SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial

Overview of attention for article published in Cardiovascular Diabetology, January 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

So far, Altmetric has seen 26 X posts from 26 X users, with an upper bound of 52,925 followers.

RT @JonathanNefro: DAPAGLIFLOZINA reduce el SODIO en la PIEL de pacientes con diabetes a únicamente 6 semanas, con ello, mejoró presiones a…

RT @JonathanNefro: DAPAGLIFLOZINA reduce el SODIO en la PIEL de pacientes con diabetes a únicamente 6 semanas, con ello, mejoró presiones a…

RT @JonathanNefro: DAPAGLIFLOZINA reduce el SODIO en la PIEL de pacientes con diabetes a únicamente 6 semanas, con ello, mejoró presiones a…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 22 additional X posts.